Cat. #161791
vRRP3 cell line
Cat. #: 161791
Organism: Human
Tissue: Skin
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Christoper Stipp
Institute: University Of Iowa Research Foundation
Primary Citation: Zhu et al. 2022. npj Precis. Onc. PMID: 36271142
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: vRRP3 cell line
- Alternate name: vRRP3
- Cancer: Skin cancer
- Research fields: Cancer;Drug development
- Parental cell: A375 Melanoma (ATCC)
- Organism: Human
- Gender: Female
- Tissue: Skin
- Donor: A375 (ATCC) -human melanoma cell line of a solid tumor from a 54-year-old female.
- Morphology: Diffuse Morphology
- Description: Drug-resistant sub-lines of A375 that are BRAF^V600E and NRAS WT. VRPP3 Harbours RAC1^N921 but does not harbour NRAS mutations or BRAF genomic alterations, which drive drug resistance through MAPK-reactivation. It is a VEM-resistant derivative of A375. vRPP3 served as a positive control as it harbours a heterozygous N92I mutation in RAC1, con?rmed via Sanger sequencing. Shows Increased VAV1 protein levels. Showed decreased MEK Phosphorylation on S217(Raf Site) and Increased MEK Phosphoryla...
- Production details: Spontaneous vemurafenib-resistant clones and populations were created after 23 and 46 weeks cultured in 3 mm vemurafenib. maintained in media with 3 mm vemurafenib.
Handling
- Growth medium: DMEM(Gibco) suplemented with penicillin/streptomycin (Gibco) and 10% FBS (Gibco).
References
- Feddersen et al.2019. Cancer Res. 79(19).PMID: 31416844
